Novo A/S »

Enliven Therapeutics shares owned by Novo A/S

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Novo A/S from 13F filings

Historical chart of Novo A/S investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Novo A/S consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Novo A/S

Quarter filed Position value Share count Share price at filing
2025-09-30 $29M 1.4M 20.47
2025-06-30 $22M 1.1M 20.06

More positions owned by Novo A/S

Vanguard Index Fds Total Stk Mkt (VTI)
Brookfield Corp Cl A Ltd Vt Sh (BN)
Asml Holding N V N Y Registry Shs (ASML)
Mirum Pharmaceuticals (MIRM)
Edgewise Therapeutics (EWTX)
salesforce (CRM)
Merus N V (MRUS)
Crinetics Pharmaceuticals In (CRNX)
Miragen Therapeutics (VRDN)
Alibaba Group Hldg Sponsored Ads (BABA)
Zenas Biopharma (ZBIO)
Pharvaris N V (PHVS)
Recursion Pharmaceuticals In Cl A (RXRX)
Arrivent Biopharma (AVBP)
BioMarin Pharmaceutical (BMRN)

View all positions for Novo A/S

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Commodore Capital
Fairmount Funds Management
BlackRock
VR Adviser
Polar Capital Holdings
Vanguard Group
Henderson Group
Novo A/S
Pictet Asset Management Holding SA
Blackstone Group
Capital Research Global Investors
Citadel Advisors
Vestal Point Capital

View all funds holding Enliven Therapeutics